Blood test may predict success of lower arthritis drug dose
NCT ID NCT06933134
First seen May 07, 2026 · Last updated May 29, 2026 · Updated 6 times
Summary
This study is testing whether a blood-based model can predict how well rheumatoid arthritis patients will respond to a lower dose of the drug rituximab. Researchers will enroll 30 adults who already respond well to standard-dose rituximab and switch them to a single 1000 mg infusion. The goal is to see if the model's prediction matches the patient's actual disease activity after six months, which could help personalize treatment and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University hospital
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.